Related Experiment Videos
Treatment of status epilepticus in children
1Dipartimento di Scienze Neurologiche e della Visione, Università di Genova, Italy.
Insights
Status epilepticus (SE) involves prolonged seizures, especially in children. Prompt treatment with antiepileptic drugs like benzodiazepines is crucial to prevent brain damage and long-term issues.
Area of Science:
- Pediatric Neurology
- Epileptology
- Critical Care Medicine
Background:
- Status epilepticus (SE) is characterized by prolonged seizures, particularly affecting the immature brain.
- Common triggers in children include fever, metabolic issues, and low antiepileptic drug levels.
- Prolonged SE (>30 minutes) can cause irreversible neuronal damage and lasting neurological deficits.
Purpose of the Study:
- To review the classification and management of status epilepticus, with a focus on pediatric cases.
- To highlight effective treatment strategies for various types of SE.
- To emphasize the importance of timely intervention in preventing sequelae.
Main Methods:
- Literature review of status epilepticus management.
- Analysis of treatment protocols for convulsive, nonconvulsive, and neonatal SE.
- Evaluation of antiepileptic drug efficacy and safety in pediatric populations.
Main Results:
- Benzodiazepines (diazepam, lorazepam, midazolam) are first-line treatments for SE.
- Midazolam infusion is effective for childhood SE, including refractory cases.
- Phenytoin and fosphenytoin are valuable for convulsive SE; phenobarbital is used in neonatal SE.
Conclusions:
- Effective management of SE requires seizure termination and treatment of underlying causes.
- The immature brain is more vulnerable to SE and its consequences.
- Appropriate and rapid administration of antiepileptic drugs is key to successful outcomes in SE.
Abstract:
Status epilepticus (SE) is a condition characterised by frequent and prolonged epileptic seizures which frequently develop in the immature brain. Fever, metabolic disorders and subtherapeutic concentrations of antiepileptic drugs are the most common factors precipitating SE in children. Progressive neuronal damage occurs if convulsive SE persists for more than 30 minutes, with neurological, epileptic and cognitive sequelae. Unfortunately, the immature brain is more predisposed to SE and its sequelae than the mature brain. SE may be categorised as convulsive, nonconvulsive or neonatal according to its responsiveness to antiepileptic drugs. Regardless of category, the main objective in the treatment of SE is to abort the seizures and treat the inciting condition. Treatment includes: (i) monitoring of hydration, electrolyte balance, and cardiocirculatory and pulmonary functions; and (ii) rapid intravenous administration of specific antiepileptic drugs. Benzodiazepines (usually diazepam, lorazepam or midazolam) are the most effective agents for the initial treatment of convulsive and nonconvulsive SE. In particular, midazolam infusion is an effective and well tolerated therapeutic approach for the management of childhood SE, including refractory SE. Phenytoin remains an excellent agent because of its long duration of action, but it is not active in nonconvulsive SE. Fosphenytoin, a phenytoin prodrug, represents a significant advance in the treatment of children with convulsive SE. Intravenous phenytoin and intramuscular phenobarbital (phenobarbitone) are generally used in neonatal SE; other agents are rarely used.